Seaport Therapeutics Revenue and Competitors
Employee Data
- Seaport Therapeutics has 45 Employees.
- Seaport Therapeutics grew their employee count by 4400% last year.
Seaport Therapeutics's People
Name | Title | Email/Phone |
---|
Seaport Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 1 | -50% | N/A | N/A |
#3 | $5.1M | 33 | 22% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 2 | -60% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 11 | 10% | N/A | N/A |
#10 | $5.4M | 29 | 0% | N/A | N/A |
What Is Seaport Therapeutics?
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. We have a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. We are led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. \n\nFor more information, please visit www.seaporttx.com or connect with us on X (formerly Twitter) @SeaportTx
keywords:N/AN/A
Total Funding
45
Number of Employees
N/A
Revenue (est)
4400%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15.1M | 45 | 18% | N/A |
#2 | $9.6M | 45 | -8% | N/A |
#3 | $7M | 45 | 32% | $46M |
#4 | $5.2M | 45 | N/A | N/A |
#5 | $9.8M | 45 | -6% | N/A |